Fig. 2.

Mutation analysis in male and female lung cancer patients. Overall, molecular pathology testing revealed no significant differences regarding the presence of gene mutations between men and women (71.8 % vs. 73.6 %, p = 0.907). (A) In male patients, treatable genetic alterations counted for 29.7 % of all detected mutations. (B) Among female patients, 52.2 % of all mutations were target mutations. Treatable EGFR-mutant, treatable KRAS-mutant, and HER-mutant lung cancers were found more frequently in female patients.